King’s College London, Intercytex and Debra Begin Phase II Trial with ICX-RHY
News Mar 15, 2011
King’s College London; Intercytex; and DEBRA, announce the start of a Phase II trial with the Intercytex therapy ICX-RHY to treat skin erosions in patients suffering from the severe genetic skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). In such patients the skin blisters at the slightest knock or rub, causing painful, open wounds which result in scarring and fusion of fingers.
The placebo controlled trial will involve 20 RDEB patients. It will be led by Professor John McGrath, Professor of Molecular Dermatology at King’s College London and Honorary Consultant Dermatologist at Guy’s and St Thomas’ NHS Foundation Trust, London, who will administer a single series of ICX-RHY injections or placebo around the margins of several selected skin erosions.
The injections will take place at the Clinical Research Facilities at Guy’s Hospital. Patients will then be assessed initially over a three month period to measure end points including time to wound closure, wound recurrence and erosion pain. The trial, which is scheduled for completion early in the autumn, is funded jointly by Intercytex, The Technology Strategy Board and DEBRA.
Professor McGrath has already used ICX-RHY successfully to treat 14 EB patients on a compassionate use basis. Commenting on the start of the trial, Prof McGrath said ‘Finding out whether a new treatment can help people with EB heal their wounds faster makes this an important clinical trial. We plan to test cells called “fibroblasts” to see if injection into the skin affects wound healing. The trial represents a significant step forward in taking research from the laboratory to the clinic.’
Melissa Smith was born with RDEB and has lived with the condition for over 24 years. Melissa took part in preliminary studies with the therapy and is now preparing to participate in the Phase ll trial. Commenting on her involvement, Melissa said ‘I am firmly committed to helping with these trials. When you have EB you live in constant pain. There is, of course, additional pain from the trial treatment but its short term and the therapy could offer such hope long term for me and others who live with EB.’
Ben Merrett, CEO of DEBRA, added: ‘Some forms of EB, like RDEB, can be very debilitating and there is a high unmet medical need for an effective treatment. Judging by the initial patient reaction to ICX-RHY, this could be an exciting step forward in treating the disease and make a significant, long-term difference to people who lead very difficult lives.’
‘I am delighted that ICX-RHY has shown such early promise in a small number of RDEB patients’ commented Dr Kemp, Intercytex’s Chief Executive Officer. ‘ICX-RHY is designated an Orphan Product in the EU and this trial marks a very significant step towards obtaining Regulatory Approval for the treatment. In the meantime we are actively looking at ways we can make this material available to other patients who are not able to be part of this trial. In addition to EB patients, ICX-RHY has also shown to have the potential to help heal burn and trauma scars and we are also trialling it in these indications.’
One in 227 people have a defective gene that causes EB and the disease affects around 1 in 17,000 live births. It is estimated that there are half a million sufferers world wide and 5,000 people with EB in the UK. RDEB is one of the more severe, debilitating forms of the disease, with a prevalence of around 2 in 100,000.
ICX-RHY is a suspension of human dermal fibroblasts (HDFs, which are naturally derived skin cells) in cell storage medium, for injection into the skin. The newly introduced HDFs are thought to repair the extracellular matrix to improve skin structure and function.
ICX-RHY is designated as one of the first Advanced Therapy Medicinal Products (ATMP) by the European Medical Agency and has already been used in clinical trials and compassionate use programmes in over 100 patients in a variety of indications.
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE